Tanaka H, Takashima H, Ubasawa M, Sekiya K, Inouye N, Baba M, Shigeta S, Walker R T, De Clercq E, Miyasaka T
School of Pharmaceutical Science, Showa University, Tokyo, Japan.
J Med Chem. 1995 Jul 21;38(15):2860-5. doi: 10.1021/jm00015a008.
Several 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (1; HEPT) were synthesized and evaluated for their anti-HIV-1 activity. LDA (lithium diisopropylamide) lithiation of 5-ethyluracil derivatives 7 and 8 and subsequent reaction with an aryl aldehyde gave 6-(arylhydroxymethyl)-5-ethyluracil derivatives 9-12. 6-(Arylhydroxymethyl)-5-isopropyluracil derivatives 15-18 were prepared from the 5-isopropyl-2-thiouracil derivatives 13 and 14 by the above procedure following oxidative hydrolysis of the thione. Preparation of the target 5-alkyl-1-(alkoxymethyl)-6-benzyluracil derivatives 27-34 was carried out by acetylation of 9-14 followed by Pd-catalyzed hydrogenolysis. The 1-butyl- (37 and 39) and 1-(2-methoxyl)- (38 and 40) 5-alkyl-6-benzyluracils were synthesized by 1-alkylation of the 3-phenacyl derivatives 35 and 36 with alkyl halides followed by deprotection of the 3-phenacyl group. Compounds synthesized in this study inhibited HIV-1 replication in MT-4 cells in the submicromolar to namomolar concentration range. From this series of compounds, 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (33) was selected for clinical evaluation.
合成了1-[(2-羟基乙氧基)甲基]-6-(苯硫基)胸腺嘧啶(1;HEPT)的几种6-苄基类似物,并对其抗HIV-1活性进行了评估。5-乙基尿嘧啶衍生物7和8经LDA(二异丙基氨基锂)锂化,随后与芳醛反应,得到6-(芳基羟甲基)-5-乙基尿嘧啶衍生物9-12。6-(芳基羟甲基)-5-异丙基尿嘧啶衍生物15-18由5-异丙基-2-硫代尿嘧啶衍生物13和14通过上述方法在硫酮氧化水解后制备。目标5-烷基-1-(烷氧基甲基)-6-苄基尿嘧啶衍生物27-34的制备是通过9-14的乙酰化,然后进行钯催化的氢解。1-丁基-(37和39)和1-(2-甲氧基)-(38和40)5-烷基-6-苄基尿嘧啶是通过3-苯甲酰衍生物35和36与卤代烃进行1-烷基化,然后脱除3-苯甲酰基合成的。本研究中合成的化合物在亚微摩尔至纳摩尔浓度范围内抑制MT-4细胞中的HIV-1复制。从这一系列化合物中,选择6-苄基-1-(乙氧基甲基)-5-异丙基尿嘧啶(33)进行临床评估。